These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 25342313)

  • 1. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
    Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
    Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
    Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
    Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.
    Olszewski AJ; Winer ES; Castillo JJ
    Leuk Res; 2014 Aug; 38(8):866-73. PubMed ID: 24837081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
    Williams JN; Rai A; Lipscomb J; Koff JL; Nastoupil LJ; Flowers CR
    Cancer; 2015 Jun; 121(11):1800-8. PubMed ID: 25675909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
    Shah BK; Bista A; Shafii B
    Anticancer Res; 2014 Sep; 34(9):5117-20. PubMed ID: 25202101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma].
    Feng J; Wu J; Song Y; Su L; Zhang M; Li W; Hu Y; Zhang X; Gao Y; Niu Z; Feng R; Wang W; Peng J; Ouyang X; Li X; Wu C; Zhang W; Zeng Y; Xiao Z; Liang Y; Zhuang Y; Wang J; Sun Z; Bai H; Cui T
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):309-13. PubMed ID: 24759018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis.
    Diem S; Ess S; Cerny T; Früh M; Hitz F
    Eur J Intern Med; 2014 Jul; 25(6):577-82. PubMed ID: 24881010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
    Castillo JJ; Winer ES; Olszewski AJ
    Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
    Hershman DL; McBride RB; Eisenberger A; Tsai WY; Grann VR; Jacobson JS
    J Clin Oncol; 2008 Jul; 26(19):3159-65. PubMed ID: 18591554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma.
    Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS
    Ann Hematol; 2012 Sep; 91(9):1383-91. PubMed ID: 22526364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
    Bittenbring JT; Neumann F; Altmann B; Achenbach M; Reichrath J; Ziepert M; Geisel J; Regitz E; Held G; Pfreundschuh M
    J Clin Oncol; 2014 Oct; 32(29):3242-8. PubMed ID: 25135997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
    Pfreundschuh M; Poeschel V; Zeynalova S; Hänel M; Held G; Schmitz N; Viardot A; Dreyling MH; Hallek M; Mueller C; Wiesen MH; Witzens-Harig M; Truemper L; Keller U; Rixecker T; Zwick C; Murawski N
    J Clin Oncol; 2014 Dec; 32(36):4127-33. PubMed ID: 25403207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of patients with transformed lymphoma in the rituximab era.
    Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
    Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.